Publication at Second Faculty of Medicine |
2018
Abstract
Ixekizumab is a new biologic drug for treatment of psoriasis and psoriatic arthritis. Ixekizumab is recombinant humanized monoclonal antibody neutralizing interleukin 17A.
The drug excels in a rapid onset of action with a reduction in PASI score by more than 50 % by the end of the second week of therapy. The high efficiency of the drug, including patients who had failed prior biological treatment, was confirmed in three double-blind, randomized, placebo-controlled clinical trials in which 89 % of the patients achieved PASI 75 and 40 % of the patients achieved PASI 100 after 12 weeks of therapy.
The ongoing high effect of the treatment was demonstrated after 2 years of treatment.